ERT and Science 37 have announced a partnership enabling ERT’s Cardiac Safety, Respiratory, and Imaging solutions to be incorporated into the Science 37 virtual, or decentralized clinical trial offering.
The ERT and Science 37 partnership enables sponsors to capture the same data in a virtual model as it would in a traditional model, while aiming to reduce patient burden, minimize patient risk, and enable study continuity.
“Given the challenges caused by COVID-19, trial sponsors need effective virtual trial solutions that enable patients to participate safely, without jeopardizing data quality,” said Jim Corrigan, CEO at ERT. “We’re pleased to partner with Science 37 and to expand the use of our Respiratory, Cardiac Safety and Imaging solutions to support virtual trials throughout the pandemic and beyond.”
During home and telemedicine visits, Science 37 will use ERT’s proven remote respiratory and cardiac safety data collection solutions. Additionally, Science 37 will leverage ERT’s Imaging services through a local-care network—helping to limit patient travel with medical imaging services closer to home.
For the full release, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.